Elevation Oncology to license an antibody drug conjugate from China's CSPC Pharma

Jul. 28, 2022 10:53 AM ETElevation Oncology, Inc. (ELEV), CHJTFBy: Anuron Mitra, SA News Editor

Close up of holding hands

Kelvin Murray

  • Elevation Oncology (NASDAQ:ELEV) on Thursday said it would give an upfront payment of $27M to CSPC Megalith Biopharmaceutical to license antibody drug conjugate EO-3021.
  • ELEV stock was down 14.2% to $1.21 in morning trading.
  • ELEV said as per the licensing agreement, it would develop and commercialize EO-3021 in all territories outside of Greater China.
  • CSPC Megalith Biopharmaceutical is a unit of China-based CSPC Pharmaceutical Group (OTCPK:CHJTF). Aside from the upfront payment, CSPC will be eligible to get $148M in development and regulatory milestone payments and up to $1B in commercial milestone payments plus royalties on net sales.
  • EO-3021 targets Claudin18.2, which is a protein expressed across several types of cancer including gastrointestinal cancers and pancreatic cancer.
  • ELEV said it was planning to start a phase 1 trial evaluating EO-3021 in the U.S. in 2023.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.